12 results on '"Cucco, Monica"'
Number of results to display per page
Search Results
2. SAT-034 Acute-on-chronic liver failure in severe acute alcoholic hepatitis: impact on management, prognostication, and urgency of liver transplantation
- Author
-
Perricone, Giovanni, primary, Mazzarelli, Chiara, additional, Viganò, Raffaella, additional, Prandoni, Paola, additional, Vangeli, Marcello, additional, Aprile, Francesca, additional, Cucco, Monica, additional, Becchetti, Chiara, additional, Stigliano, Rosa, additional, Cesarini, Lucia, additional, Scaravaglio, MIki, additional, Monti, Gianpaola, additional, Lauterio, Andrea, additional, Airoldi, Aldo, additional, and Belli, Luca Saverio, additional
- Published
- 2024
- Full Text
- View/download PDF
3. Comparison of point shear wave elastography and transient elastography in the evaluation of patients with NAFLD
- Author
-
Argalia, Giulio, Ventura, Claudio, Tosi, Niccolò, Campioni, Daniele, Tagliati, Corrado, Tufillaro, Marianna, Cucco, Monica, Svegliati Baroni, Gianluca, and Giovagnoni, Andrea
- Published
- 2022
- Full Text
- View/download PDF
4. Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort
- Author
-
Mazzaro, Cesare, Bertola, Manuela, Schioppa, Ornella, Benedetti, Antonio, Schiadà, Laura, Cucco, Monica, Giacometti, Andrea, Brescini, Laura, Castelletti, Sefora, Fiorentini, Alessandro, Angarano, Gioacchino, Milella, Michele, Di Leo, Alfredo, Rendina, Maria, D'abramo, Fulvio Salvatore, Lillo, Chiara, Iannone, Andrea, Piazzolla, Mariano, Verucchi, Gabriella, Badia, Lorenzo, Piscaglia, Fabio, Benevento, Francesca, Serio, Ilaria, Castelli, Francesco, Zaltron, Serena, Spinetti, Angiola, Odolini, Silvia, Bruno, Raffaele, Mondelli, Mario, Chessa, Luchino, Loi, Martina, Torti, Carlo, Costa, Chiara, Mazzitelli, Maria, Pisani, Vincenzo, Scaglione, Vincenzo, Trecarichi, Enrico Maria, Zignego, Anna Linda, Monti, Monica, Madia, Francesco, Blanc, Pier Luigi, Attala, Letizia, Pierotti, Piera, Salomoni, Elena, Mariabelli, Elisa, Santantonio, Teresa Antonia, Bruno, Serena Rita, Cela, Ester Marina, Bassetti, Matteo, Mazzarello, Giovanni, Alessandrini, Anna Ida, Di Biagio, Antonio, Nicolini, Laura Ambra, Raimondo, Giovanni, Filomia, Roberto, Aghemo, Alessio, Meli, Rossella, Lazzarin, Adriano, Morsica, Giulia, Salpietro, Stefania, Galli, Massimo, Fracanzani, Anna Ludovica, Fatta, Erika, Lombardi, Rosa, Lampertico, Pietro, Borghi, Marta, D'ambrosio, Roberta, Degasperi, Elisabetta, Puoti, Massimo, Baiguera, Chiara, D'amico, Federico, Vinci, Maria, Rumi, Maria Grazia, Zuin, Massimo, Giorgini, Alessia, Zermiani, Paola, Andreone, Pietro, Caraceni, Paolo, Margotti, Marzia, Guarneri, Valeria, Villa, Erica, Bernabucci, Veronica, Bristot, Laura, Paradiso, Maria Luisa, Migliorino, Guglielmo, Beretta, Ilaria, Gambaro, Alessandra, Lapadula, Giuseppe, Spolti, Anna, Soria, Alessandro, Invernizzi, Pietro, Ciaccio, Antonio, LucÀ, Martina, Malinverno, Federica, Ratti, Laura, Coppola, Carmine, Amoruso, Daniela Caterina, Pisano, Federica, Scarano, Ferdinando, Staiano, Laura, Morisco, Filomena, Cossiga, Valentina, Gentile, Ivan, Buonomo, Antonio Riccardo, Foggia, Maria, Zappulo, Emanuela, Federico, Alessandro, Dallio, Marcello, Coppola, Nicola, Sagnelli, Caterina, Martini, Salvatore, Monari, Caterina, Nardone, Gerardo, Sgamato, Costantino, Chemello, Liliana, Cavalletto, Luisa, Sterrantino, Daniela, Russo, Francesco Paolo, Zanetto, Alberto, Zanaga, Paola, Barbaro, Francesco, Brancaccio, Giuseppina, Craxì, Antonio, Petta, Salvatore, Calvaruso, Vincenza, Crapanzano, Luciano, Madonia, Salvatore, Cannizzaro, Marco, Bruno, Erica Maria, Licata, Anna, Amodeo, Simona, Capitano, Adele Rosaria, Ferrari, Carlo, Laccabue, Diletta, Negri, Elisa, Orlandini, Alessandra, Pesci, Marco, Gulminetti, Roberto, Pagnucco, Layla, Parruti, Giustino, Di Stefano, Paola, Brunetto, Maurizia Rossana, Coco, Barbara, Massari, Marco, Corsini, Romina, Garlassi, Elisa, Andreoni, Massimo, Teti, Elisabetta, Cerva, Carlotta, Baiocchi, Lorenzo, Tata, Xhimi, Grassi, Giuseppe, Gasbarrini, Antonio, Pompili, Maurizio, De Siena, Martina, Taliani, Gloria, Biliotti, Elisa, Spaziante, Martina, Persico, Marcello, Masarone, Mario, Aglitti, Andrea, Calvanese, Gemma, Anselmo, Marco, De Leo, Pasqualina, Marturano, Monica, Saracco, Giorgio Maria, Ciancio, Alessia, Ieluzzi, Donatella, Quaranta, Maria Giovanna, Ferrigno, Luigina, D'Angelo, Franca, Saracino, Annalisa, and Kondili, Loeta A.
- Published
- 2021
- Full Text
- View/download PDF
5. Predicting de‐novoportal vein thrombosis after HCV eradication: A long‐term competing risk analysis in the ongoing PITER cohort
- Author
-
Kondili, Loreta A., Zanetto, Alberto, Quaranta, Maria Giovanna, Ferrigno, Luigina, Panetta, Valentina, Calvaruso, Vincenza, Zignego, Anna Linda, Brunetto, Maurizia R., Raimondo, Giovanni, Biliotti, Elisa, Ieluzzi, Donatella, Iannone, Andrea, Madonia, Salvatore, Chemello, Liliana, Cavalletto, Luisa, Coppola, Carmine, Morisco, Filomena, Barbaro, Francesco, Licata, Anna, Federico, Alessandro, Cerini, Federica, Persico, Marcello, Pompili, Maurizio, Ciancio, Alessia, Piscaglia, Fabio, Chessa, Luchino, Giacometti, Andrea, Invernizzi, Pietro, Brancaccio, Giuseppina, Benedetti, Antonio, Baiocchi, Leonardo, Gentile, Ivan, Coppola, Nicola, Nardone, Gerardo, Craxì, Antonio, Russo, Francesco Paolo, Monti, Monica, Coco, Barbara, Filomia, Roberto, Bruno, Erica Maria, Cossiga, Valentina, Amodeo, Simona, Dallio, Marcello, Crapanzano, Luciano, Masarone, Mario, De Siena, Martina, Serio, Ilaria, Loi, Martina, Brescini, Lucia, Ciaccio, Antonio, Cucco, Monica, Tata, Xhimi, Sagnelli, Caterina, Sgamato, Costantino, Claar, Ernesto, Rosselli Del Turco, Elena, Rumi, Maria Grazia, Gaeta, Giovanni Battista, and Simioni, Paolo
- Abstract
Sustained virological response (SVR) by direct‐acting antivirals (DAAs) may reverse the hypercoagulable state of HCV cirrhosis and the portal vein thrombosis (PVT) risk. We evaluated the incidence and predictive factors of de novo, non‐tumoral PVT in patients with cirrhosis after HCV eradication. Patients with HCV‐related cirrhosis, consecutively enrolled in the multi‐center ongoing PITER cohort, who achieved the SVR using DAAs, were prospectively evaluated. Kaplan‐Meier and competing risk regression analyses were performed. During a median time of 38.3 months (IQR: 25.1–48.7 months) after the end of treatment (EOT), among 1609 SVR patients, 32 (2.0%) developed de novo PVT. A platelet count ≤120,000/μL, albumin levels ≤3.5 mg/dL, bilirubin >1.1 mg/dL, a previous liver decompensation, ALBI, Baveno, FIB‐4, and RESIST scores were significantly different (p< 0.001), among patients who developed PVT versus those who did not. Considering death and liver transplantation as competing risk events, esophageal varices (subHR: 10.40; CI 95% 4.33–24.99) and pre‐treatment ALBI grade ≥2 (subHR: 4.32; CI 95% 1.36–13.74) were independent predictors of PVT. After HCV eradication, a significant variation in PLT count, albumin, and bilirubin (p< 0.001) versus pre‐treatment values was observed in patients who did not develop PVT, whereas no significant differences were observed in those who developed PVT (p> 0.05). After the EOT, esophageal varices and ALBI grade ≥2, remained associated with de novo PVT (subHR: 9.32; CI 95% 3.16–27.53 and subHR: 5.50; CI 95% 1.67–18.13, respectively). In patients with HCV‐related cirrhosis, a more advanced liver disease and significant portal hypertension are independently associated with the de novo PVT risk after SVR.
- Published
- 2024
- Full Text
- View/download PDF
6. Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002–2033: the ITA.LI.CA database
- Author
-
Vitale, Alessandro, primary, Svegliati-Baroni, Gianluca, additional, Ortolani, Alessio, additional, Cucco, Monica, additional, Dalla Riva, Giulio V, additional, Giannini, Edoardo G, additional, Piscaglia, Fabio, additional, Rapaccini, Gianludovico, additional, Di Marco, Mariella, additional, Caturelli, Eugenio, additional, Zoli, Marco, additional, Sacco, Rodolfo, additional, Cabibbo, Giuseppe, additional, Marra, Fabio, additional, Mega, Andrea, additional, Morisco, Filomena, additional, Gasbarrini, Antonio, additional, Foschi, Francesco Giuseppe, additional, Missale, Gabriele, additional, Masotto, Alberto, additional, Nardone, Gerardo, additional, Raimondo, Giovanni, additional, Azzaroli, Francesco, additional, Vidili, Gianpaolo, additional, Oliveri, Filippo, additional, Pelizzaro, Filippo, additional, Ramirez Morales, Rafael, additional, Cillo, Umberto, additional, Trevisani, Franco, additional, Miele, Luca, additional, Marchesini, Giulio, additional, and Farinati, Fabio, additional
- Published
- 2021
- Full Text
- View/download PDF
7. Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002-2033: the ITA.LI.CA database.
- Author
-
Vitale, Alessandro, Svegliati-Baroni, Gianluca, Ortolani, Alessio, Cucco, Monica, Riva, Giulio V. Dalla, Giannini, Edoardo G., Piscaglia, Fabio, Rapaccini, Gianludovico, Di Marco, Mariella, Caturelli, Eugenio, Zoli, Marco, Sacco, Rodolfo, Cabibbo, Giuseppe, Marra, Fabio, Mega, Andrea, Morisco, Filomena, Gasbarrini, Antonio, Foschi, Francesco Giuseppe, Missale, Gabriele, and Masotto, Alberto
- Subjects
HEPATOCELLULAR carcinoma ,FATTY liver ,MEDICAL personnel ,HEPATITIS C ,MEDICAL sciences ,MEDICAL specialties & specialists ,NON-alcoholic fatty liver disease - Published
- 2023
- Full Text
- View/download PDF
8. Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002-2033: the ITA.LI.CA database
- Author
-
Vitale, Alessandro, Svegliati-Baroni, Gianluca, Ortolani, Alessio, Cucco, Monica, Dalla Riva, Giulio V, Giannini, Edoardo G, Piscaglia, Fabio, Rapaccini, Gianludovico, Di Marco, Mariella, Caturelli, Eugenio, Zoli, Marco, Sacco, Rodolfo, Cabibbo, Giuseppe, Marra, Fabio, Mega, Andrea, Morisco, Filomena, Gasbarrini, Antonio, Foschi, Francesco Giuseppe, Missale, Gabriele, Masotto, Alberto, Nardone, Gerardo, Raimondo, Giovanni, Azzaroli, Francesco, Vidili, Gianpaolo, Oliveri, Filippo, Pelizzaro, Filippo, Ramirez Morales, Rafael, Cillo, Umberto, Trevisani, Franco, Miele, Luca, Marchesini, Giulio, Farinati, Fabio, Gasbarrini, Antonio (ORCID:0000-0002-7278-4823), Miele, Luca (ORCID:0000-0003-3464-0068), Vitale, Alessandro, Svegliati-Baroni, Gianluca, Ortolani, Alessio, Cucco, Monica, Dalla Riva, Giulio V, Giannini, Edoardo G, Piscaglia, Fabio, Rapaccini, Gianludovico, Di Marco, Mariella, Caturelli, Eugenio, Zoli, Marco, Sacco, Rodolfo, Cabibbo, Giuseppe, Marra, Fabio, Mega, Andrea, Morisco, Filomena, Gasbarrini, Antonio, Foschi, Francesco Giuseppe, Missale, Gabriele, Masotto, Alberto, Nardone, Gerardo, Raimondo, Giovanni, Azzaroli, Francesco, Vidili, Gianpaolo, Oliveri, Filippo, Pelizzaro, Filippo, Ramirez Morales, Rafael, Cillo, Umberto, Trevisani, Franco, Miele, Luca, Marchesini, Giulio, Farinati, Fabio, Gasbarrini, Antonio (ORCID:0000-0002-7278-4823), and Miele, Luca (ORCID:0000-0003-3464-0068)
- Abstract
Background Metabolic dysfunction-associated fatty liver disease (MAFLD) represents a new inclusive definition of the whole spectrum of liver diseases associated to metabolic disorders. The main objective of this study was to compare patients with MAFLD and non-MAFLD with hepatocellular carcinoma (HCC) included in a nationally representative cohort. Methods We analysed 6882 consecutive patients with HCC enrolled from 2002 to 2019 by 23 Italian Liver Cancer centres to compare epidemiological and future trends in three subgroups: pure, single aetiology MAFLD (S-MAFLD); mixed aetiology MAFLD (metabolic and others, M-MAFLD); and non-MAFLD HCC. Results MAFLD was diagnosed in the majority of patients with HCC (68.4%). The proportion of both total MAFLD and S-MAFLD HCC significantly increased over time (from 50.4% and 3.6% in 2002-2003, to 77.3% and 28.9% in 2018-2019, respectively, p<0.001). In Italy S-MAFLD HCC is expected to overcome M-MAFLD HCC in about 6 years. Patients with S-MAFLD HCC were older, more frequently men and less frequently cirrhotic with clinically relevant portal hypertension and a surveillance-related diagnosis. They had more frequently large tumours and extrahepatic metastases. After weighting, and compared with patients with non-MAFLD, S-MAFLD and M-MAFLD HCC showed a significantly lower overall (p=0.026, p=0.004) and HCC-related (p<0.001, for both) risk of death. Patients with S-MAFLD HCC showed a significantly higher risk of non-HCC-related death (p=0.006). Conclusions The prevalence of MAFLD HCC in Italy is rapidly increasing to cover the majority of patients with HCC. Despite a less favourable cancer stage at diagnosis, patients with MAFLD HCC have a lower risk of HCC-related death, suggesting reduced cancer aggressiveness.
- Published
- 2021
9. Mechanisms for increased risk of diabetes in chronic liver diseases
- Author
-
Svegliati‐Baroni, Gianluca, primary, Gaggini, Melania, additional, Carli, Fabrizia, additional, Barbieri, Chiara, additional, Cucco, Monica, additional, Younes, Ramy, additional, Rosso, Chiara, additional, Bugianesi, Elisabetta, additional, and Gastaldelli, Amalia, additional
- Published
- 2020
- Full Text
- View/download PDF
10. Usefulness of the index of NASH – ION for the diagnosis of steatohepatitis in patients with non‐alcoholic fatty liver: An external validation study
- Author
-
Younes, Ramy, primary, Rosso, Chiara, additional, Petta, Salvatore, additional, Cucco, Monica, additional, Marietti, Milena, additional, Caviglia, Gian Paolo, additional, Ciancio, Alessia, additional, Abate, Maria Lorena, additional, Cammà, Carlo, additional, Smedile, Antonina, additional, Craxì, Antonio, additional, Saracco, Giorgio Maria, additional, and Bugianesi, Elisabetta, additional
- Published
- 2017
- Full Text
- View/download PDF
11. Usefulness of the index of NASH – ION for the diagnosis of steatohepatitis in patients with non‐alcoholic fatty liver: An external validation study.
- Author
-
Younes, Ramy, Rosso, Chiara, Cucco, Monica, Marietti, Milena, Caviglia, Gian Paolo, Ciancio, Alessia, Abate, Maria Lorena, Smedile, Antonina, Saracco, Giorgio Maria, Bugianesi, Elisabetta, Petta, Salvatore, Cammà, Carlo, and Craxì, Antonio
- Subjects
FATTY liver ,FIBROSIS ,DIAGNOSIS ,PATIENTS ,THERAPEUTICS ,DISEASE risk factors - Abstract
Abstract: Background & Aims: The non‐invasive identification of steatohepatitis (NASH) in patients with Non‐Alcoholic Fatty Liver Disease is an unmet need in clinical practice. Index of NASH (ION) is a new tool for the prediction of NASH. We aimed to externally validate ION and to compare it with CK‐18. Since necroinflammation precedes fibrosis, we also tested ION in combination with non‐invasive tools for fibrosis. Methods: We analysed data from 292 Italian patients (169 Southern cohort, and 123 Northern cohort) with an histological diagnosis of NAFLD. The ION, FIB‐4 and NFS scores were calculated according to published algorithms. Serum cytokeratin18‐Aspartate396 levels and liver stiffness (LS) by Fibroscan were assessed within three months from liver biopsy. Results: The diagnostic accuracy of ION for the identification of NASH was not as satisfactory as reported (area under the ROC curve, AUROC = 0.687 [95% CI = 0.62‐0.75]). The proposed cut‐off value ≥50 showed a poor sensitivity (Se) (28%) and a good specificity (Sp) (92%), with a positive predictive value (PPV) of 91% and a negative predictive value (NPV) of 30%. A new cut‐off value >26 improved Se (73%) but decreased Sp (60%) (PPV of 84% and a NPV of 43%). ION performed slightly better in obese NAFLD (AUROC = 0.700). The combination of ION and markers of fibrosis did not improve the identification of advanced liver disease. Conclusions: ION is not feasible for the non‐invasive diagnosis of NASH across different populations of NAFLD patients, mainly because its limited reproducibility in non‐obese subjects. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
12. Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002-2033: The ITA.LI.CA database
- Author
-
Alessandro, Vitale, Gianluca, Svegliati-Baroni, Alessio, Ortolani, Monica, Cucco, Giulio V, Dalla Riva, Edoardo G, Giannini, Fabio, Piscaglia, Gianludovico, Rapaccini, Mariella, Di Marco, Eugenio, Caturelli, Marco, Zoli, Rodolfo, Sacco, Giuseppe, Cabibbo, Fabio, Marra, Andrea, Mega, Filomena, Morisco, Antonio, Gasbarrini, Francesco Giuseppe, Foschi, Gabriele, Missale, Alberto, Masotto, Gerardo, Nardone, Giovanni, Raimondo, Francesco, Azzaroli, Gianpaolo, Vidili, Filippo, Oliveri, Filippo, Pelizzaro, Rafael, Ramirez Morales, Umberto, Cillo, Franco, Trevisani, Luca, Miele, Giulio, Marchesini, Fabio, Farinati, Alessandro, Di Bucchianico, Vitale, A., Svegliati-Baroni, G., Ortolani, A., Cucco, M., Dalla Riva, G. V., Giannini, E. G., Piscaglia, F., Rapaccini, G., Di Marco, M., Caturelli, E., Zoli, M., Sacco, R., Cabibbo, G., Marra, F., Mega, A., Morisco, F., Gasbarrini, A., Foschi, F. G., Missale, G., Masotto, A., Nardone, G., Raimondo, G., Azzaroli, F., Vidili, G., Oliveri, F., Pelizzaro, F., Ramirez Morales, R., Cillo, U., Trevisani, F., Miele, L., Marchesini, G., Farinati, F., Alessandro Vitale, Gianluca Svegliati-Baroni, Alessio Ortolani, Monica Cucco, Giulio V Dalla Riva, Edoardo G Giannini, Fabio Piscaglia, Gianludovico Rapaccini, Mariella Di Marco, Eugenio Caturelli, Marco Zoli, Rodolfo Sacco, Giuseppe Cabibbo, Fabio Marra, Andrea Mega, Filomena Morisco, Antonio Gasbarrini, Francesco Giuseppe Foschi, Gabriele Missale, Alberto Masotto, Gerardo Nardone, Giovanni Raimondo, Francesco Azzaroli, Gianpaolo Vidili, Filippo Oliveri, Filippo Pelizzaro, Rafael Ramirez Morales, Umberto Cillo, Franco Trevisani, Luca Miele, Giulio Marchesini, Fabio Farinati, Vitale, Alessandro, Svegliati-Baroni, Gianluca, Ortolani, Alessio, Cucco, Monica, Dalla Riva, Giulio V, Giannini, Edoardo G, Piscaglia, Fabio, Rapaccini, Gianludovico, Di Marco, Mariella, Caturelli, Eugenio, Zoli, Marco, Sacco, Rodolfo, Cabibbo, Giuseppe, Marra, Fabio, Mega, Andrea, Morisco, Filomena, Gasbarrini, Antonio, Foschi, Francesco Giuseppe, Missale, Gabriele, Masotto, Alberto, Nardone, Gerardo, Raimondo, Giovanni, Azzaroli, Francesco, Vidili, Gianpaolo, Oliveri, Filippo, Pelizzaro, Filippo, Ramirez Morales, Rafael, Cillo, Umberto, Trevisani, Franco, Miele, Luca, Marchesini, Giulio, and Farinati, Fabio
- Subjects
Male ,Settore MED/12 - Gastroenterologia ,Carcinoma, Hepatocellular ,Liver Neoplasms ,nonalcoholic steatohepatitis ,Gastroenterology ,hepatocellular carcinoma ,digestive system diseases ,Non-alcoholic Fatty Liver Disease ,Risk Factors ,Humans ,neoplasms - Abstract
BackgroundMetabolic dysfunction-associated fatty liver disease (MAFLD) represents a new inclusive definition of the whole spectrum of liver diseases associated to metabolic disorders. The main objective of this study was to compare patients with MAFLD and non-MAFLD with hepatocellular carcinoma (HCC) included in a nationally representative cohort.MethodsWe analysed 6882 consecutive patients with HCC enrolled from 2002 to 2019 by 23 Italian Liver Cancer centres to compare epidemiological and future trends in three subgroups: pure, single aetiology MAFLD (S-MAFLD); mixed aetiology MAFLD (metabolic and others, M-MAFLD); and non-MAFLD HCC.ResultsMAFLD was diagnosed in the majority of patients with HCC (68.4%). The proportion of both total MAFLD and S-MAFLD HCC significantly increased over time (from 50.4% and 3.6% in 2002–2003, to 77.3% and 28.9% in 2018–2019, respectively, pConclusionsThe prevalence of MAFLD HCC in Italy is rapidly increasing to cover the majority of patients with HCC. Despite a less favourable cancer stage at diagnosis, patients with MAFLD HCC have a lower risk of HCC-related death, suggesting reduced cancer aggressiveness.
- Published
- 2021
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.